PRE-084 Stats & Data

Name hygiene: no credible primary sources link PRE-084 to the alias “Fenclimorate”; retaining that name risks misidentification during procurement or verification. PubChem lists PRE-084 under the cyclohexanecarboxylate/morpholine ester names noted above. PRE-084 is a selective σ1 receptor agonist used as a research ligand; rodent work shows rapid CNS penetration and a plasma half-life near 3.3 h, but human pharmacokinetics remain unknown. σ1 receptor agonism modulates monoaminergic and glutamatergic signaling and can change the behavioural/toxic profile of stimulants; σ1 antagonists (BD1018/BD1063) attenuate several cocaine effects in mice, implying that σ1 agonists could do the opposite. Several SSRIs interact with σ1 (fluvoxamine/fluoxetine/escitalopram as agonists; sertraline with antagonist/inverse agonist properties), making co-use effects unpredictable. Dextromethorphan is itself a σ1 agonist and can interact at σ1 in animal models; combining high-dose DXM with PRE-084 may magnify or alter effects in either direction. Sparse human reports suggest mild mental stimulation, clarity, and occasionally insomnia; schedule daytime trials and avoid late dosing. Because identity/purity vary by vendor, weigh doses on a 0.001 g scale, and adjust for salt form (HCl ≈10–12% heavier than freebase for equivalent molar dose). Avoid inhalation/vaping routes—thermal decomposition profile is unknown for this ester; insufflation can be irritating and may increase bioavailability unpredictably. People with a history of seizures should avoid σ1 agonist stacks; some σ1-active agents (e.g., opipramol) showed proconvulsant effects in a PTZ-kindling mouse model. As a research chemical without established therapeutic window in humans, employ allergy test dosing (e.g., ≤1 mg) and increase only after ≥24 h with no adverse effects. Polysubstance ‘potentiation’ experiments (e.g., with psychedelics or dissociatives) carry poorly characterized risks due to σ1’s broad cellular roles—avoid until single-agent response is well understood.